Llwytho...
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C
Daclatasvir (Daklinza™), a new oral direct-acting antiviral, is an inhibitor of hepatitis C virus NS5A protein and has recently been approved in the United States, Europe and Japan in chronic hepatitis C. It shows potent pangenotypic activity and moderately high genetic barrier to resistance improvi...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ann Gastroenterol |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Hellenic Society of Gastroenterology
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4923813/ https://ncbi.nlm.nih.gov/pubmed/27366028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20524/aog.2016.0041 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|